This week, ZenPharm, the Maltese joint venture with Canadian cannabis producer, Zenabis Global, received its Maltese licence to process cannabis for medicinal use and research purposes out of its Hal Far Industrial Estate premises.
Kurt Farrugia, CEO of Malta Enterprise – the national economic development agency that assisted the company to set up locally – considers this “an important milestone for Malta’s medical cannabis industry.”
“We are gaining momentum with the production of cannabis for medical use in Malta,” he wrote. “Zenabis – a Maltese joint venture and partner of Zenpharm, have received a licence for the production of medical cannabis in their facility in Hal Far, Malta.”
The CEO said that the issuing of the second licence for the production of cannabis for medical use shows that “Malta is becoming a centre of excellence in such an important emerging sector.”
“Those companies strive hard to achieve the Medicine’s Authority pharmaceutical standards. Now that they do, patients can rest assured that the Made in Malta product is top quality. A gold standard for the industry. This is indeed a proud moment.”
Through its licence, ZenPharm plans to ship around 500kg of cannabis out of Malta annually to EU countries, with the largest market being Germany.
Featured Image:
Kurt Farrugia / LinkedIn
Joseph Mifsud Grima named to Captive Review’s 2026 Forty Under 40 list
'I am incredibly honoured.'
Aġenzija Sapport CEO: ‘People underestimate what someone with a disability can bring to the table’
'Subtle double-takes, lowered expectations, and quiet assumptions.'
Robert Metsola: ‘If Europe wants to lead, we need to take risks’
She believes Europe needs to take risks to deliver results and strengthen its position as a competitive economic force.
‘Money down the drain’ or ‘existential threat to Malta’? Equinox CEO unpacks EU Inc.
Bernard Mallia warns EU Inc. could weaken Malta’s competitive edge.
